The Effect of Caffeine on Ischemic Preconditioning - Full Text View

Sponsors and Collaborators:	Radboud University ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by:	Radboud University
ClinicalTrials.gov Identifier:	NCT00184912

Purpose

Ischaemic preconditioning (IP) describes the phenomenon that brief periods of ischaemia render the (myocardial) muscle more resistant to a subsequent more prolonged period of ischaemia and reperfusion. Animal studies have provided evidence that adenosine receptor stimulation is an important mediator of IP. As caffeine is an effective adenosine receptor antagonist already at concentrations reached after regular coffee consumption, we aimed to assess whether caffeine impairs IP in humans in vivo. We used a novel and well-validated model to study IP in humans: 99m-Tc-annexin A5 scintigraphy in forearm skeletal muscle.

24 healthy volunteers were randomly assigned to either caffeine (4 mg/kg/iv in 10 minutes) or saline before a protocol for IP.

Condition	Intervention
Caffeine Ischemic Preconditioning Ischemia-Reperfusion Injury	Drug: caffeine Drug: Technetium-TC99m-labeled Annexin A5 Procedure: ten minutes forearm ischemia Procedure: ischemic forearm exercise

MedlinePlus related topics: Caffeine

Drug Information available for: 3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione Caffeine citrate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Randomized, Double-Blind, Placebo Control, Parallel Assignment
Official Title:	Caffeine Reduces Acute Ischemic Preconditioning

Further study details as provided by Radboud University:

Primary Outcome Measures:

Percentual difference in Annexin A5 targetting between the experimental and control arm one and four hours after intravenous injection.

Estimated Enrollment:	24
Study Start Date:	September 2003
Estimated Study Completion Date:	January 2006

Eligibility

Ages Eligible for Study:	18 Years to 50 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

healthy male volunteers

Exclusion Criteria:

-

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00184912

Locations

Netherlands, Gelderland
Radboud University Nijmegen Medical Centre / Department of Pharmacology and Toxicology
Nijmegen, Gelderland, Netherlands, 6500 HB

Sponsors and Collaborators

Radboud University

ZonMw: The Netherlands Organisation for Health Research and Development

Investigators

Principal Investigator:

Gerard Rongen, MD, Phd

Radboud University Nijmegen Medical Centre / Department of pharmacology and Toxicology

More Information

Publications of Results:

Riksen NP, Zhou Z, Oyen WJ, Jaspers R, Ramakers BP, Brouwer RM, Boerman OC, Steinmetz N, Smits P, Rongen GA. Caffeine prevents protection in two human models of ischemic preconditioning. J Am Coll Cardiol. 2006 Aug 15;48(4):700-7. Epub 2006 Jul 24.

Other Publications:

Rongen GA, Oyen WJ, Ramakers BP, Riksen NP, Boerman OC, Steinmetz N, Smits P. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation. 2005 Jan 18;111(2):173-8. Epub 2004 Dec 27.

Study ID Numbers:	CAFIRI
Study First Received:	September 12, 2005
Last Updated:	November 28, 2006
ClinicalTrials.gov Identifier:	NCT00184912
Health Authority:	Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Study placed in the following topic categories:

Caffeine citrate
Postoperative Complications
Citric Acid
Vascular Diseases

Annexin A5
Caffeine
Ischemia
Reperfusion Injury

Additional relevant MeSH terms:

Phosphodiesterase Inhibitors
Pathologic Processes
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Physiological Effects of Drugs

Central Nervous System Stimulants
Enzyme Inhibitors
Cardiovascular Diseases
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009